Tradestie Institutional Equity Comparison Engine

IBO vs GRML โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus GRML at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against GRML sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
IBO N/M vs GRML N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin -12621.0% vs N/A ยท YoY +16.7% vs N/A
Momentum & Technical Winner IBO
1Y +872.5% vs +650.0% ยท 52W Pos 68% vs 19%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
1M Return +85.07%
1Y Return +872.55%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
1M Return -41.5%
1Y Return +650.0%
Forward P/E N/M
Unified AI Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBO +872.55% GRML +650.0% Spread: +135.56 pp (IBO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBO TTM Op. Margin: -12621.0% GRML TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs GRML. Trailing 12-month operating profitability (IBO -12621.0% vs GRML N/A) and valuation multiples (IBO N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBO (7) vs GRML (2)
Institutional Metric IBO GRML Criterion Row Winner
Market Capitalization Scale $41.2M N/A Larger Scale IBO
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +16.7% N/A Higher Growth IBO
Operating Margin (TTM) Profitability -12621.0% N/A Higher Margin IBO
Net Profit Margin Profitability 4247.4% N/A Higher Margin IBO
Return on Equity (ROE) Capital Efficiency 71.2% N/A Higher ROE IBO
52-Week Range Position Momentum 68% ($0โ€“$7) 19% ($0โ€“$18) Stronger Trend IBO
Beta / 30D Volatility Risk Regime -6.75ฮฒ ยท 120% Vol -5.32ฮฒ ยท 95% Vol Lower Realized Risk GRML
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 56.8 / 100 (HOLD) Higher Composite GRML

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBO vs GRML Buy Guide
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GRML UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GRML Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBO nor GRML registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.